Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: Toxicity and efficacy study

Kazuyuki Imai, Anat Loewenstein, Barba Koroma, Rhonda Grebe, Eugene De Juan

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Proliferative vitreoretinopathy (PVR) is partially caused by peptide growth factors, stimulating the cell by binding to a transmembrane tyrosine kinase receptor. We studied the effects of herbimycin A (HA), a tyrosine kinase inhibitor, in PVR. Methods: Toxicity studies: Electroretinography and histological studies were performed after intravitreal injection of HA. Efficacy studies: Homologous rabbit dermal fibroblasts were injected intravitreally, followed by injection of HA. The presence of tractional retinal detachment (TRD) and severity of inflammation were assessed. Results: Toxicity studies: Eyes injected with HA exhibited decrease in B-wave amplitude initially, with subsequent recovery. Histologically, damage to photoreceptors was evident after injection of high but not of low doses of HA. Efficacy studies: Inflammatory response and the development of TRD were significantly reduced with all doses of HA.. Conclusions: HA (20 μM) was found to be effective and safe in preventing the development of inflammation and TRD.

Original languageEnglish
Pages (from-to)440-447
Number of pages8
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume238
Issue number5
DOIs
StatePublished - May 2000

Fingerprint

Dive into the research topics of 'Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: Toxicity and efficacy study'. Together they form a unique fingerprint.

Cite this